<SEC-DOCUMENT>0001193125-24-011267.txt : 20240119
<SEC-HEADER>0001193125-24-011267.hdr.sgml : 20240119
<ACCEPTANCE-DATETIME>20240119161952
ACCESSION NUMBER:		0001193125-24-011267
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240119
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240119
DATE AS OF CHANGE:		20240119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROKIDNEY CORP.
		CENTRAL INDEX KEY:			0001850270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981586514
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40560
		FILM NUMBER:		24545837

	BUSINESS ADDRESS:	
		STREET 1:		2000 FRONTIS PLAZA BLVD.
		STREET 2:		SUITE 250
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103
		BUSINESS PHONE:		336-999-7028

	MAIL ADDRESS:	
		STREET 1:		2000 FRONTIS PLAZA BLVD.
		STREET 2:		SUITE 250
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Social Capital Suvretta Holdings Corp. III
		DATE OF NAME CHANGE:	20210310
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d664610d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prok="http://www.prokidney.com/20240119" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-01-19_to_2024-01-19">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-01-19_to_2024-01-19">0001850270</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="prok-20240119.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2024-01-19_to_2024-01-19"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-19</xbrli:startDate> <xbrli:endDate>2024-01-19</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-01-19_to_2024-01-19">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt:datemonthdayyearen">January 19, 2024</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-01-19_to_2024-01-19">PROKIDNEY CORP.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:edgarprovcountryen">Cayman Islands</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-01-19_to_2024-01-19">001-40560</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-01-19_to_2024-01-19">98-1586514</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-01-19_to_2024-01-19">2000 Frontis Plaza Blvd.</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-01-19_to_2024-01-19">Suite 250</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-01-19_to_2024-01-19">Winston-Salem</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:stateprovnameen">North Carolina</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-01-19_to_2024-01-19">27103</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-01-19_to_2024-01-19">336</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-01-19_to_2024-01-19">999-7029</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-01-19_to_2024-01-19">Class&#160;A ordinary shares, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-01-19_to_2024-01-19">PROK</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:exchnameen">The Nasdaq Stock Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-01-19_to_2024-01-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;1.01 Entry Into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;19, 2024, ProKidney Corp. (the &#8220;Company&#8221;) entered into an Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (the &#8220;Sales Agent&#8221;), pursuant to which the Company may offer and sell, from time to time, shares (the &#8220;Shares&#8221;) of its Class&#160;A ordinary shares, par value $0.0001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $100,000,000 through the Sales Agent, acting as agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Sales Agreement, sales of the Shares may be made by any method permitted that is deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in ordinary brokers&#8217; transactions, to or through a market maker, on or through The Nasdaq Capital Market or any other market venue where the securities may be traded, in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, in privately negotiated transactions or through a combination of any such methods of sale. Under the Sales Agreement, the Sales Agent will be entitled to compensation of up to 3.0% of the gross offering proceeds of all Shares sold through it pursuant to the Sales Agreement. The Company also will reimburse the Sales Agent for certain specified expenses in connection with entering into the Sales Agreement. The Company has no obligation to sell any of the Shares under the Sales Agreement and may at any time and from time to time suspend the offering of the Shares under the Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Agreement contains customary representations, warranties and covenants by the Company. The Company also agreed to provide indemnification and contribution to the Sales Agent against certain liabilities, including under the Securities Act and the Securities Exchange Act of 1934, as amended. From time to time, in the ordinary course of business, the Sales Agent has provided, and in the future may provide, various financial advisory and investment banking services to the Company, for which they have received or will receive customary fees and reimbursement of expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any sales of Shares under the Sales Agreement will be made pursuant to the Company&#8217;s shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-275701),</span> including the related prospectus, filed with the Securities and Exchange Commission on November&#160;22, 2023 and declared effective on November&#160;30, 2023, and any applicable prospectus supplements that form a part of the Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of certain provisions of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is filed as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Walkers LLP relating to the validity of the Shares to be issued pursuant to the&#160;Sales Agreement is filed herewith as Exhibit 5.1 hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Sales Agreement, nor shall there be any sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description of Exhibit</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d664610dex11.htm">Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup>, dated January&#160;19, 2024, by and between ProKidney Corp. and Jefferies LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d664610dex51.htm">Opinion of Walkers. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d664610dex51.htm">Consent of Walkers (included in Exhibit&#160;5.1 hereto). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">PROKIDNEY CORP.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: January&#160;19, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd Girolamo</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name: &#160;&#160;Todd Girolamo</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title: &#160;&#160;&#160;&#160;Chief Legal Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d664610dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OPEN MARKET SALE AGREEMENT</U><SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">January&nbsp;19, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ProKidney Corp., a
Cayman Islands exempted company (the &#147;<B>Company</B>&#148;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the &#147;<B>Agent</B>&#148;),
the Company&#146;s Class&nbsp;A Ordinary Shares, par value $0.0001 per share (the &#147;<B>Ordinary Shares</B>&#148;), having an aggregate offering price of up to $100,000,000 on the terms set forth in this agreement (this
&#147;<B>Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Certain Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the
following respective meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; of a Person means another Person that directly or indirectly, through one or
more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#147;control&#148; (including the terms &#147;controlling,&#148; &#147;controlled by&#148; and &#147;under common control
with&#148;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agency Period</B>&#148; means the period commencing on the date of this Agreement and expiring on the earliest to occur of
(x)&nbsp;the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y)&nbsp;the date this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Floor Price</B>&#148; means the minimum price set by the Company in the Issuance Notice below which the Agent shall
not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in
no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#146;s sole discretion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Open Market Sale Agreement&#148; is a service mark of Jefferies LLC
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Amount</B>&#148; means the aggregate Sales Price of the Shares to be sold
by the Agent pursuant to any Issuance Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice</B>&#148; means a written notice delivered to the Agent by the
Company in accordance with this Agreement in the form attached hereto as <U>Exhibit A</U> that is executed by its Chief Executive Officer, President or Chief Financial Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice Date</B>&#148; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to
<U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Price</B>&#148; means the Sales Price less the Selling Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Maximum Program Amount</B>&#148; means Ordinary Shares with an aggregate Sales Price of the lesser of (a)&nbsp;the number or dollar
amount of Ordinary Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)&nbsp;the number of authorized but unissued Ordinary Shares (less Ordinary Shares issuable upon
exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#146;s authorized capital stock), (c) the number or dollar amount of Ordinary Shares permitted to be sold under Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (including General Instruction I.B.6 thereof, if applicable), or (d)&nbsp;the number or dollar amount of Ordinary Shares for which the Company has filed a Prospectus (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated
association, joint venture, joint stock company, governmental authority or other entity of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Principal Market</B>&#148;
means the Nasdaq Capital Market or such other national securities exchange on which the Ordinary Shares, including any Shares, are then listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 462(b) Registration Statement</B>&#148; means any registration statement filed by the Company pursuant to Rule 462(b) under the
Securities Act in connection with the offer and sale of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Price</B>&#148; means the actual sale execution price of
each Share placed by the Agent pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as
amended, and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Selling Commission</B>&#148; means up to three percent (3%)
of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Settlement Date</B>&#148; means the second business day following each Trading Day during the period set forth in the Issuance Notice
on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shares</B>&#148; shall mean the Company&#146;s Ordinary Shares issued or issuable
pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Day</B>&#148; means any day on which the Principal Market is open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to, and agrees with, the Agent that as of (1)&nbsp;the date of this Agreement, (2)&nbsp;each Issuance
Notice Date, (3)&nbsp;each Settlement Date, (4)&nbsp;each Triggering Event Date and (5)&nbsp;as of each Time of Sale (each of the times referenced above is referred to herein as a &#147;<B>Representation Date</B>&#148;), except as may be disclosed
in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement</U>. The Company has prepared and filed with the Commission a shelf registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (file No. <FONT STYLE="white-space:nowrap">333-275701)&nbsp;that</FONT> contains a base prospectus (the &#147;<B>Base Prospectus</B>&#148;). Such registration statement registers the issuance and sale
by the Company of the Shares under the Securities Act. The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with
respect to the Shares. Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits
and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act as from time to time amended or supplemented, is
herein referred to as the &#147;<B>Registration Statement</B>,&#148; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the
Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act,
in each case, as from time to time amended or supplemented, is referred to herein as the &#147;<B>Prospectus</B>,&#148; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the
Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#147;<B>Prospectus</B>&#148; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such
use. The Registration Statement at the time it originally became effective is herein called the &#147;<B>Original Registration Statement</B>.&#148; As used in this Agreement, the terms &#147;amendment&#148; or &#147;supplement&#148; when applied to
the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which is &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is
deemed to be incorporated by reference in or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date; and all references in this
Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference
in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time the Registration Statement was or will be originally declared effective and at the time the Company&#146;s most recent annual
report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> was filed with the Commission, if later, the Company met the then-applicable requirements for use of <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> under the Securities Act.
During the Agency Period, each time the Company files an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> the Company will meet the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Compliance with Registration Requirements</U>. The Original Registration Statement has been declared effective by
the Commission under the Securities Act, and any Rule&nbsp;462(b) Registration Statement will be declared effective by the Commission under the Securities Act prior to the first Issuance Notice. The Company will and has complied to the
Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of the Registration Statement or any Rule&nbsp;462(b) Registration Statement is in
effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus when filed will comply in all material respects with the Securities Act and, if filed with the Commission through its
Electronic Data Gathering, Analysis and Retrieval system (&#147;<B>EDGAR</B>&#148;) (except as may be permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act), was identical to the copy thereof delivered to
the Agent for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any Rule&nbsp;462(b) Registration Statement and any post-effective amendment thereto, at the time it became effective and at all subsequent
times, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading. As of the date of this Agreement, the Prospectus, and, if available for use, any Free Writing Prospectus (as defined below) considered together (collectively, the &#147;<B>Time of Sale Information</B>&#148;) did
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus, as amended or supplemented,
as of its date and at all subsequent times, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule&nbsp;462(b) Registration Statement, or any
post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein,
it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in <U>Section</U><U></U><U>&nbsp;6</U> below. There are no contracts or other documents required to be
described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of
Rule 415 under the Securities Act and comply in all material respects with said rule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Ineligible Issuer Status</U>. The Company shall cease to be an &#147;ineligible
issuer&#148; on July&nbsp;11, 2025, pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is then eligible to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with
the Commission in accordance with the requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is then eligible to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or behalf of or
used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free
Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the
information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to you before first use,
the Company has not prepared, used or referred to, and will not, without your prior written consent, which consent shall not be unreasonably withheld or conditioned, prepare, use or refer to, any Free Writing Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Incorporated Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the
Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus, do not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exchange Act Compliance</U>. The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they
were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other
information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each Time of Sale (as defined below), as the case may be, will not contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Statistical and Market-Related Data</U>. All statistical, demographic and <FONT STYLE="white-space:nowrap">market-related</FONT> data
included in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate. To the extent required, the Company has obtained the written consent for
the use of such data from such sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control
Over Financial Reporting</U>. The Company has established and maintains disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange
Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial officer by others
within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#146;s
most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of the Company&#146;s most recent audited fiscal year, there have been no significant
deficiencies or material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>This Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Authorization of the Shares</U>. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued
and delivered by the Company against payment therefor pursuant to this Agreement and the register of members of the Company has been updated by the transfer agent of the Company to reflect the issuance of the Shares, will be validly issued, fully
paid and nonassessable, and the issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>No Applicable Registration or Other Similar Rights</U>. There are no persons with registration or other similar rights to have any
equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived or satisfied prior to the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>No Material Adverse Change</U>. Except as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to the
respective dates as of which information is given in the Registration Statement and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development that would reasonably be expected to result in a material adverse change, in
(A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company
and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a &#147;<B>Material
Adverse Change</B>&#148;); (ii)&nbsp;the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with
their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any
transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has
been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or
redemption by the Company or any of its subsidiaries of any class of capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Independent Accountants</U>. Ernst&nbsp;&amp;
Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement and the Prospectus, is
(i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii) in compliance with the applicable
requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm
as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Financial Statements</U>. The financial statements filed with the Commission as a part of the Registration Statement and the Prospectus
present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity and cash flows for the periods
specified. Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in
the related notes thereto and except in the case of unaudited financial statements, which are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain all footnotes as permitted by the
applicable rules of the Commission. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been
prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus. The financial data set
forth in each of the Registration Statement and the Prospectus fairly present the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement and the Prospectus. To the
Company&#146;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or
otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Company&#146;s Accounting System</U>. The Company and each of its subsidiaries make and keep books and records that are accurate in all
material respects and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s
general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in
eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Incorporation and Good Standing of the Company</U><I>.</I> The Company
has been duly incorporated and is validly existing as a corporation in good standing (where such concept is recognized) under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its
properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and
is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing, as the case may
be, would not result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Subsidiaries.</U> Each of the Company&#146;s &#147;subsidiaries&#148; (for
purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good
standing (where such concept is recognized) under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as
described in the Registration Statement and the Prospectus. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing
(where such concept is recognized) in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing,
as the case may be, would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are
fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding capital stock or equity interest in
any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each of the subsidiaries comply in all material respects with the requirements of
applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in
Exhibit&nbsp;21 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Capitalization and Other Capital Stock Matters</U>. The authorized, issued and outstanding capital stock of the Company is as set forth
in the Registration Statement and the Prospectus under the caption &#147;Description of Shares&#148; (other than for subsequent issuances, if any, pursuant to employee benefit plans described in the Prospectus or upon the exercise of outstanding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options or warrants, in each case described in the Registration Statement and the Prospectus). The Ordinary Shares (including the Shares) conform in all material respects to the description
thereof contained in the Prospectus. All of the issued and outstanding Ordinary Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all applicable federal and state securities
laws. None of the outstanding Ordinary Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options,
warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those
described in the Registration Statement and the Prospectus. The descriptions of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration
Statement and the Prospectus accurately and fairly presents, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Stock Exchange Listing</U>. The Ordinary Shares are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and are
listed on the Principal Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Ordinary Shares under the Exchange Act or delisting the Ordinary Shares from the Principal market,
nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance with all applicable listing requirements of the
Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further Authorizations or
Approvals Required</U>. Neither the Company nor any of its subsidiaries is in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as
applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument
(including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by
which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an &#147;<B>Existing Instrument</B>&#148;), except for such Defaults as would not be expected, individually or in the aggregate, to
result in a Material Adverse Change. The Company&#146;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement and the Prospectus and the issuance and sale of the
Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement and the Prospectus under the caption &#147;Use of Proceeds&#148;) (i)&nbsp;have been duly authorized by all necessary corporate action and
will not result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary
(ii)&nbsp;will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the
Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, except as would not be expected to result in a Material Adverse Change,and (iii)&nbsp;will not result in any violation of any law,
administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries. No consent, approval, authorization or other order of, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and
consummation of the transactions contemplated hereby and by the Registration Statement and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required
under applicable state securities, the laws of the Cayman Islands, or blue sky laws or FINRA (as defined below). As used herein, a &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition which gives, or with the giving of
notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>No Material Actions or Proceedings</U>. Except as otherwise disclosed in
the Prospectus, there is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its
subsidiaries, which would be expected, individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company or any of its subsidiaries, or, to the knowledge of the Company, with the
employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or is threatened or imminent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)
<U>Intellectual Property Rights</U>. Except as otherwise disclosed in the Registration Statement or the Prospectus, the Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications,
patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their
respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#147;<B>Intellectual Property</B>&#148;) and, to the Company&#146;s knowledge, the conduct of their respective businesses does not and will not
infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. The Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in
part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except for customary
reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement and the Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii)&nbsp;there is no
infringement by third parties of any Intellectual Property. There is no pending or threatened in writing action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company
is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would
form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in
the Registration Statement or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which
would form a reasonable basis for any such action, suit, proceeding or claim. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are
in full force and effect. To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect,
maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and no employee of the Company
is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement,
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company. The
duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property have been complied with; and in all foreign
offices having similar requirements, all such requirements have been complied with. None of the Company owned Intellectual Property or technology (including information technology and outsourced arrangements) employed by the Company or its
subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in
violation of the rights of any persons. The product candidates described in the Registration Statement and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or
exclusively licensed to, the Company or any subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>All Necessary Permits, etc</U>. Except as otherwise disclosed in the
Prospectus, the Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and
as described in the Registration Statement or the Prospectus (&#147;<B>Permits</B>&#148;), except where the failure to or possess or obtain the same would not reasonably be expected to result in Material Adverse Change. Neither the Company nor any
of its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such
certificate, authorization or permit, except for such violation, defaults or proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any such Permits, that would not reasonably be
expected to result in Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Title to Properties</U>. Except as otherwise disclosed in the Prospectus, the
Company and its subsidiaries has good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in <U>Section</U><U></U><U>&nbsp;2(m)</U> above (or elsewhere in the
Registration Statement or the Prospectus, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects. The real property, improvements, equipment and personal property held under
lease by the Company or of its subsidiary are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment
or personal property by the Company or such subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Tax Law Compliance</U>. The Company and its subsidiaries have filed all necessary
federal, state and foreign income and franchise tax returns required to be filed by them or have properly requested extensions thereof and have paid all material taxes required to be paid by any of them and, if due and payable, any related or
similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial statements
referred to in <U>Section</U><U></U><U>&nbsp;2(m)</U> above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally
determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Company Not an &#147;Investment Company.&#148;</U> The Company is not, and will not be, either after receipt of
payment for the Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement or the Prospectus, required to register as an &#147;investment company&#148; under the Investment
Company Act of 1940, as amended (the <B>&#147;Investment Company Act&#148;)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Insurance</U>. Except as otherwise disclosed in
the Prospectus, each of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and
customary for their businesses including, but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies
covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as
and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to result in a
Material Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>No Price Stabilization or Manipulation; Compliance with Regulation M</U>. Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Ordinary Shares or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act
(<B>&#147;Regulation M&#148;</B>)) with respect to the Ordinary Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>Related Party Transactions</U>. There are no business relationships or related-party transactions involving the Company or any of its
subsidiaries or any other person required to be described in the Registration Statement or the Prospectus which have not been described as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>FINRA Matters</U>. All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers
and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete, correct and compliant with Financial Industry Regulatory Authority,
Inc.&#146;s (&#147;<B>FINRA</B>&#148;) rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules&nbsp;or NASD Conduct Rules is true, complete and correct. The Company meets the requirements for use of
Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act specified in FINRA Rule 5110(h)(1). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>No Unlawful Contributions or Other Payments</U>. Except as otherwise disclosed in
the Prospectus, neither the Company nor any of its subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate
for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Compliance with Environmental Laws</U>. Except as described in the Prospectus and except as would not be reasonably expected,
individually or in the aggregate, to result in a Material Adverse Change; (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, &#147;<B>Environmental Laws</B>&#148;), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their
requirements, (iii)&nbsp;there are no pending administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings, and to the Company&#146;s knowledge, no
such matters have been threatened in writing, relating to any Environmental Law against the Company or any of its subsidiaries and (iv)&nbsp;there are no events or circumstances that might reasonably be expected to form the basis of an order for <FONT
STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any
Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>Periodic Review of Costs of Environmental Compliance</U>. In the ordinary course of its business, the Company
conducts a periodic review of the effect of Environmental Laws on the business, operations and properties of the Company and its subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities (including, without
limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating
activities and any potential liabilities to third parties). No facts or circumstances have come to the Company&#146;s attention that could result in costs or liabilities that could be expected, individually or in the aggregate, to result in a
Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>ERISA Compliance</U>. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries
and any &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or
maintained by the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ERISA. &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections&nbsp;414(b), (c), (m) or
(o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#147;<B>Code</B>&#148;) of which the Company or such subsidiary is a member. No &#147;reportable event&#148; (as defined
under ERISA) has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No &#147;employee benefit plan&#148;
established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA).
Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i)&nbsp;Title&nbsp;IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit
plan&#148; or (ii)&nbsp;Sections&nbsp;412, 4971, 4975 or 4980B of the Code. Each &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under
Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>Broker</U><U>s</U>. Except as otherwise disclosed in the Prospectus, there is no broker, finder or other party that is entitled to
receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>No Outstanding Loans or Other Extensions of Credit</U>. The Company does not have any outstanding extension of credit, in the form of
a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>Compliance with Laws</U>. The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and
regulations, except where failure to be so in compliance could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Dividend Restrictions</U>. Except as disclosed in the Prospectus, no subsidiary of the Company is prohibited or restricted, directly
or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#146;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time
to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>Anti-Corruption and Anti-Bribery Laws</U>. Neither the Company nor any of its subsidiaries nor any director, officer or employee of
the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any
of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made or taken any act in furtherance of an offer, promise, or authorization
of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;<B>FCPA</B>&#148;), the UK
Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful
payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Money Laundering
Laws</U>. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency
(collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the
Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>Clinical Data and Regulatory
Compliance.</U> The preclinical tests and clinical trials, and other studies (collectively, &#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still
pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of
such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or
otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug
Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or Institutional Review Board (collectively, the
&#147;<B>Regulatory Agencies</B>&#148;); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are
described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the
Regulatory Agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <U>Sanctions.</U> Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to
the knowledge of the Company, after due inquiry, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&#146;s Treasury of the United Kingdom, or other relevant sanctions
authority (collectively, &#147;<B>Sanctions</B>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Sanctions, including, without limitation, Zaporizhzhia and Kherson Regions of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT
STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Cuba, Iran, North Korea and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the
target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years,
the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with
any Sanctioned Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>Sarbanes-Oxley</U>. The Company is in compliance, in all material respects, with all applicable
provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <U>Duties, Transfer Taxes,
Etc</U>. No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other taxes are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection
with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)
<U>Choice of Law</U>. Under the laws of the Cayman Islands and as set out in the Prospectus, the courts of the Cayman Islands will recognize and give effect to the choice of law provisions set forth in Section&nbsp;8(g) hereof and enforce judgments
of U.S. courts obtained against the Company, the choice of law provisions set forth in Section&nbsp;8(g) hereof will be recognized by the courts of the Cayman Islands and any judgment obtained in any state or federal court located in the Borough of
Manhattan, The City of New York, New York arising out of or in relation to the obligations of the Company under this Agreement will be recognized in Cayman Islands courts relating to the enforceability of foreign judgments and the statements set
forth in the Prospectus under the caption &#147;Enforcement of Civil Liabilities&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Cybersecurity</U>. The Company and its
subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural
person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank
information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended; (iii) &#147;personal data&#148; as defined by GDPR; (iv)&nbsp;any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and
Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of information that allows the identification of such natural
person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except
for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material
compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security
of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <U>Compliance with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with
all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25,
2018, have been and currently are in material compliance with, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with the Privacy
Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the
collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory
rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The
Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or
condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is
a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <U>Other Underwriting
Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other &#147;at the market&#148; or continuous equity transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <U>Compliance with Health Care Laws</U>. The Company and its subsidiaries are, and at all times have been, in compliance with all
applicable Health Care Laws. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; means, as applicable to the Company and its subsidiaries: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the
Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback
Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C.
Section&nbsp;1320a-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;<B>HIPAA</B>&#148;) (42 U.S.C.
Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare
programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and
Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational
and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart
thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory
authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or
other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care
Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent
submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory
authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human
clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for
the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>
hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. ISSUANCE AND SALE OF ORDINARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Sale of Securities</U>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales
Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Mechanics of Issuances</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Issuance Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on
which the conditions set forth in <U>Section</U><U></U><U>&nbsp;5(a)</U> and <U>Section</U><U></U><U>&nbsp;5(b)</U> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance
Notice; <I>provided, however</I>, that (A)&nbsp;in no event may the Company deliver an Issuance Notice to the extent that (I)&nbsp;the sum of (x)&nbsp;the aggregate Sales Price of the requested Issuance Amount, plus (y)&nbsp;the aggregate Sales
Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B)&nbsp;prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice
shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by <FONT STYLE="white-space:nowrap">e-mail</FONT> to the persons set forth in Schedule A hereto and confirmed by the
Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Agent Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice,
the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information
specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may
modify an Issuance Notice at any time provided they both agree in writing to any such modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Method of Offer and
Sale</U>. The Shares may be offered and sold (A)&nbsp;in privately negotiated transactions with the consent of the Company; (B)&nbsp;as block transactions; or (C)&nbsp;by any other method permitted by law deemed to be an &#147;at the market
offering&#148; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Principal Market or sales made into any other existing trading market of the Ordinary Shares. Nothing in this Agreement shall be deemed to
require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clauses (A)&nbsp;and (B) above) the method of placement of any Shares by the Agent shall be at the Agent&#146;s
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Confirmation to the Company</U>. If acting as sales agent hereunder, the Agent will provide written confirmation to
the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable
to the Company in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Settlement</U>. Each issuance of Shares will be settled on the applicable Settlement Date for
such issuance of Shares and, subject to the provisions of <U>Section</U><U></U><U>&nbsp;5</U>, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares being sold by crediting the Agent or its designee&#146;s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of
delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of
immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant
time Shares are sold pursuant to this Agreement (each, a &#147;<B>Time of Sale</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Suspension or Termination of
Sales</U>. Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period
set forth in an Issuance Notice shall immediately terminate; <I>provided, however</I>, that (A)&nbsp;such suspension and termination shall not affect or impair either party&#146;s obligations with respect to any Shares placed or sold hereunder prior
to the receipt of such notice; (B)&nbsp;if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with <U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with
respect to such Shares; and (C)&nbsp;if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation,
penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent
may borrow Ordinary Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v)&nbsp;above, and may use the Shares to settle or close out such borrowings. The Company agrees that no
such notice shall be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>No Guarantee of Placement, Etc.</U> The Company acknowledges and agrees that (A)&nbsp;there can be no assurance that the Agent will
be successful in placing Shares; (B)&nbsp;the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and (C)&nbsp;the Agent shall be under no obligation to purchase Shares on a principal basis
pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Material <FONT
STYLE="white-space:nowrap">Non-Public</FONT> Information.</U> Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be
obligated to place any Shares, during any period in which the Company is in possession of material <FONT STYLE="white-space:nowrap">non-public</FONT> information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Fees</U>. As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling
Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(vi))</U> by the Agent deducting the Selling Commission from the applicable Issuance Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations
hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs); (ii)&nbsp;all fees and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses of the registrar and transfer agent of the Shares; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares; (iv)&nbsp;all
fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors; (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the
Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of, used by, or referred to by the Company,
and all amendments and supplements thereto, and this Agreement; (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the
qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and printing a &#147;<B>Blue Sky
Survey</B>&#148; or memorandum and a &#147;Canadian wrapper,, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii)&nbsp;the reasonable fees and disbursements of the Agent&#146;s
counsel, including&nbsp;the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#146;s participation in the offering and distribution of the Shares; (viii)&nbsp;the filing fees
incident to FINRA review, if any; (ix)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including, without
limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road
show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with
the road show; and (x)&nbsp;the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#146;s counsel pursuant to subsections (vi)&nbsp;and (vii) above shall not exceed (A) $75,000 in
connection with the execution of this Agreement and (B) $15,000 in connection with each Triggering Event Date (as defined below) on which the Company is required to provide a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4. ADDITIONAL COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this
Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exchange Act Compliance</U>. During the Agency Period, the Company shall (i)&nbsp;file, on a timely basis, with the
Commission all reports and documents required to be filed under Section&nbsp;13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and (ii)&nbsp;either (A) include in its quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and its annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> a summary detailing, for the relevant reporting period, (1)&nbsp;the number of Shares sold through the Agent pursuant to this
Agreement and (2)&nbsp;the net proceeds received by the Company from such sales or (B)&nbsp;prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#147;<B>Interim
Prospectus Supplement</B>&#148;), such summary information and, at least once a quarter and subject to this Section&nbsp;4, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods
required by Rule 424(b) and Rule 430B under the Securities Act)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Securities Act Compliance</U>. After the date of this Agreement, the Company shall
promptly advise the Agent in writing (i)&nbsp;of the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;of the time and date of any filing of any post-effective amendment to the
Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, any Free Writing Prospectus; (iii)&nbsp;of the time and date that any post-effective amendment to the Registration Statement or any Rule
462(b) Registration Statement becomes effective; and (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration
Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the
Ordinary Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop
order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under
the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including
the Securities Act, the Company agrees (subject to Section&nbsp;4(d) and 4(f)) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the
Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered
to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent&#146;s consent to, or delivery of, any such amendment or supplement shall constitute
a waiver of any of the Company&#146;s obligations under Sections 4(d) and 4(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent</U><U>&#146;</U><U>s Review of Proposed
Amendments and Supplements</U>.<I> </I>Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule&nbsp;462(b) under the Securities Act) or the Prospectus (excluding any amendment or
supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment
or supplement, insofar as such proposed amendment or supplement relates to the transactions contemplated hereby, and the Company shall not file or use any such proposed amendment or supplement without the Agent&#146;s prior consent, and to file with
the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Use of Free Writing Prospectus</U>. Neither the Company nor the Agent has prepared,
used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#146;s prior written consent, any &#147;written communication&#148; that constitutes a &#147;free writing prospectus&#148; as such terms are
defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#147;<B>Free Writing Prospectus</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Free Writing Prospectuses</U>. When eligible to use a free writing prospectus, the Company shall furnish to the Agent for review, a
reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company insofar
as such proposed free writing prospectus or amendment or supplement relates to the transactions contemplated hereby and the Company shall not file, use or refer to any such proposed free writing prospectus or any such amendment or supplement thereto
without the Agent&#146;s consent. The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus prepared by or on behalf of, or used by the Company insofar as such proposed free writing prospectus relates to
the transactions contemplated hereby, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule&nbsp;173(d)) to be delivered in connection with sales of
the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by
the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements
in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at
such subsequent time, not misleading, as the case may be; <I>provided, however</I>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the
proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Agent&#146;s
consent, not to be unreasonably withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Filing of Agent Free Writing Prospectuses</U>. The Company shall not take any action
that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been
required to file thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Copies of Registration Statement and Prospectus</U>. After the date of this Agreement through the
last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule&nbsp;173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be
electronic copies) of the Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the Securities Act or Rule&nbsp;424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required
under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and
if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act
any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such
offers as soon as practicable); and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare
and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however,
that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Blue Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for
sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such
qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of
process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such
exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or
exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Earnings
Statement</U>. As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal
quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Listing; Reservation of Shares</U>. (a)&nbsp;The Company will use its best efforts to maintain the listing of the Shares on the
Principal Market; and (b)&nbsp;the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Transfer Agent</U>. The Company shall engage and maintain, at its expense, a
registrar and transfer agent for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Due Diligence</U>. During the term of this Agreement, the Company will reasonably
cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers,
during normal business hours and at the Company&#146;s principal offices, as the Agent may reasonably request from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)
<U>Representations and Warranties</U>. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i)&nbsp;an affirmation to the Agent that the representations and
warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be
disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto); and (ii)&nbsp;an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true
and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the
Prospectus as amended and supplemented relating to such Shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Deliverables at Triggering Event Dates; Certificates.</U> The
Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus
supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section&nbsp;4(a)(ii)(B)), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents
by reference into the Registration Statement or Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) the filing with the Commission of an annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (including any Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q/A</FONT> containing
amended financial information or a material amendment to the previously filed annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q),</FONT> in each case, of the Company;
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) the filing with the Commission of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company containing
amended financial information (other than information &#147;furnished&#148; pursuant to Item 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or to provide disclosure pursuant to Item 8.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) that is material to the offering of securities of
the Company in the Agent&#146;s reasonable discretion; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(any such event, a &#147;<B>Triggering Event Date</B>&#148;), the Company shall furnish the Agent
(but in the case of clause (C)&nbsp;above only if the Agent reasonably determines that the information contained in such current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company is material) with a certificate as of the
Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented,
(A)&nbsp;confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B)&nbsp;that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such
certificate and as to the matters set forth in <U>Section</U><U></U><U>&nbsp;5(a)(iii)</U> hereof, and (C)&nbsp;containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this
<U>Section</U><U></U><U>&nbsp;4(o)</U> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company
delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to
sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this Section&nbsp;4(o), then before the Company delivers the instructions for the sale of Shares or the Agent sells
any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this Section&nbsp;4(o) dated as of the date that the instructions for the sale of Shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Legal Opinions.</U> On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to
which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(o) for which no waiver is applicable and excluding the date of this Agreement, a negative assurances letter and the written legal opinion of Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C., U.S. counsel to the Company, Walkers (Cayman) LLP, Cayman Islands counsel to the Company, Paul Hastings LLP, counsel to the Agent, each dated the date of delivery, in form and substance reasonably satisfactory to
Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions
for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage
of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event Date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Comfort Letter</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to
which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause Ernst&nbsp;&amp; Young LLP, the independent registered public
accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the
Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to the extent that it contains
financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent upon a material transaction or event requiring the filing of a current
report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> containing material amended financial information of the Company, including the restatement of the Company&#146;s financial statements, which such events shall be considered a Triggering
Event Date, the Company shall also cause a comfort letter to be furnished to the Agent prior to any additional sales of Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Secretary</U><U>&#146;</U><U>s Certificate</U>. On or prior to the date of the first
Issuance Notice and on or prior to each Triggering Event Date, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i)&nbsp;certifying that attached thereto
are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without
limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii)&nbsp;certifying and attesting to the office, incumbency, due authority and
specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii)&nbsp;containing any other certification that the Agent shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Agent&#146;s Own Account; Clients&#146; Account</U>. The Company consents to the Agent trading, in compliance with applicable law, in
the Ordinary Shares for the Agent&#146;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Investment Limitation</U>. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the
Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Market Activities</U>. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected
to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its affiliates to,
comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (&#147;<B>Rule 102</B>&#148;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in
Section (d)&nbsp;of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its affiliates to, comply with Rule 102 as though such exception were not available
but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d)&nbsp;of Rule 102. <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Notice of Other Sale</U>. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any Ordinary Shares or securities convertible into or exchangeable for Ordinary Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Ordinary Shares,
during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares
sold pursuant to such Issuance Notice; and will not directly or indirectly enter into any other &#147;at the market&#148; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any
Ordinary Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Ordinary Shares, warrants or any rights to purchase or acquire, Ordinary Shares prior to the termination of this Agreement;
provided, however, that such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictions will not be required in connection with the Company&#146;s (i)&nbsp;issuance or sale of Ordinary Shares, options to purchase Ordinary Shares or Ordinary Shares issuable upon the
exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or
other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii)&nbsp;issuance or sale of Ordinary Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of
warrants, options or other equity awards outstanding at the date of this Agreement, and (iii)&nbsp;modification of any outstanding options, warrants of any rights to purchase or acquire Ordinary Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</U>. The
right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the
applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance, of each of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Accuracy of the Company&#146;s Representations and Warranties; Performance by the Company</U>. The Company
shall have delivered the certificate required to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> on or before the date on which delivery of such certificate is required pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>. The Company
shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants
contained in <U>Section</U><U></U><U>&nbsp;4(p)</U>, <U>Section</U><U></U><U>&nbsp;4(q)</U> and <U>Section</U><U></U><U>&nbsp;4(r)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially
adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Material Adverse Changes</U>. Except as disclosed in the Prospectus and the Time of Sale Information,
(a)&nbsp;in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b)&nbsp;there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any
review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating organization&#148; as
such term is defined for purposes of Section&nbsp;3(a)(62) of the Exchange Act. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Suspension of Trading in or Delisting of Ordinary Shares; Other Events</U>. The trading of the Ordinary
Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Ordinary Shares (including without limitation the Shares) shall have been approved for listing or quotation on
and shall not have been delisted from the the Nasdaq Stock Market, the New York Stock Exchange or any of their constituent markets. There shall not have occurred (and be continuing in the case of occurrences under clauses (i)&nbsp;and (ii) below)
any of the following: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally on either the Principal Market shall
have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or the FINRA; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal or
New York, authorities; or (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial
change or development involving a prospective substantial change in United States&#146; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the
Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documents Required to be Delivered on each Issuance Notice Date</U>. The Agent&#146;s obligation to use its commercially reasonable
efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive
Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate shall not be required if the
foregoing representations shall be set forth in the Issuance Notice). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Misstatement or Material Omission</U>. Agent shall not
have advised the Company that the Registration Statement, the Prospectus or the Times of Sales Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#146;s reasonable opinion is material, or
omits to state a fact that in the Agent&#146;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. INDEMNIFICATION AND CONTRIBUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification of the Agent</U>. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each
person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been
offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule&nbsp;430B under the Securities Act, or the
omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free
Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by the Agent in connection
with, or relating in any manner to, the Ordinary Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause
(i)&nbsp;or (ii) above, provided that the Company shall not be liable under this clause (iii)&nbsp;to the extent that a court of competent jurisdiction shall have determined by a final judgment that such loss, claim, damage, liability or action
resulted directly from any such acts or failures to act undertaken or omitted to be taken by the Agent through its bad faith or willful misconduct, and to reimburse the Agent and each such officer, employee and controlling person for any and all
expenses (including the reasonable and documented fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating,
defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but
only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for
use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the
information set forth in the first sentence of the ninth paragraph under the caption &#147;Plan of Distribution&#148; in the Prospectus under the caption &#147;Plan of Distribution&#148; in the Prospectus (the &#147;<B>Agent Information</B>&#148;).
The indemnity agreement set forth in this <U>Section</U><U></U><U>&nbsp;6(a)</U> shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification of the Company</U>. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its
officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or
any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been
offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any
untrue statement or alleged untrue statement of a material fact contained in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission
therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the
Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i)&nbsp;and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in reliance upon and in conformity with the Agent Information, and to reimburse the Company and each such director, officer and controlling person for any and all reasonable and documented expenses
(including the reasonable and documented fees and disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director or controlling person in connection with investigating,
defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this Section&nbsp;6(b) shall be in addition to any liabilities that the Agent or the Company may otherwise
have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notifications and Other Indemnification Procedures</U>. Promptly after receipt by an indemnified party under this
<U>Section</U><U></U><U>&nbsp;6</U> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U>, notify the
indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity
agreement contained in this <U>Section</U><U></U><U>&nbsp;6</U> or to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends
to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action
include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of
any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select
separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such
indemnifying party&#146;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this <U>Section</U><U></U><U>&nbsp;6</U> for any
legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it
being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action),
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which counsel (together with any local counsel) for the indemnified parties shall be selected by the Agent (in the case of counsel for the indemnified parties referred to in
<U>Section</U><U></U><U>&nbsp;6(a)</U><B> </B>above), (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of
the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense
of the indemnifying party and shall be paid as they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Settlements</U>. The indemnifying party under this
<U>Section</U><U></U><U>&nbsp;6</U> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to
indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel as contemplated by <U>Section</U><U></U><U>&nbsp;6(c)</U> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its
written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such indemnifying party of the aforesaid request; and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance
with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened
action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Contribution</U>. If the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;6</U> is for any reason held to be
unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or
payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the
one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement; or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses,
claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares
pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent.
The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to
state a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U>, any legal or other fees or expenses reasonably incurred by such party in connection with
investigating or defending any action or claim. The provisions set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this
<U>Section</U><U></U><U>&nbsp;6(c)</U>; <I>provided, however,</I> that no additional notice shall be required with respect to any action for which notice has been given under <U>Section</U><U></U><U>&nbsp;6(c)</U> for purposes of indemnification.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this
<U>Section</U><U></U><U>&nbsp;6(e)</U> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this <U>Section</U><U></U><U>&nbsp;6(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, the Agent shall not be required to contribute any amount in
excess of the agent fees received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the
Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company with
the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.
TERMINATION&nbsp;&amp; SURVIVAL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of this <U>Section</U><U></U><U>&nbsp;7</U>, the term of
this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination; Survival Following Termination</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as
required by this Agreement, upon ten (10)&nbsp;Trading Days&#146; notice to the other party; provided that, (A)&nbsp;if the Company terminates this Agreement after the Agent confirms to <U>the Company any sale of Shares</U>, the Company shall remain
obligated to <U>comply with Section</U><U></U><U>&nbsp;3(b)(v) with respect to such Shares</U> and (B)<U>&nbsp;Section</U><U></U><U>&nbsp;2</U>, <U>Section</U><U></U><U>&nbsp;6</U>, <U>Section</U><U></U><U>&nbsp;7</U> and
<U>Section</U><U></U><U>&nbsp;8</U> shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to the survival provision of <U>Section</U><U></U><U>&nbsp;7(b)(i)</U>, the respective indemnities,
agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf
of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold
hereunder and any termination of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8. MISCELLANEOUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Press Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions contemplated
hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> with this Agreement attached as an exhibit thereto, describing the
material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text
for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure required in reports filed with the
Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of
the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party
prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Advisory or Fiduciary Relationship</U>.<B> </B>The Company acknowledges and agrees that (i)&nbsp;the transactions contemplated by
this Agreement, including the determination of any fees, are <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transactions between the Company and the Agent, (ii)&nbsp;when acting as a principal under this Agreement, the Agent is
and has been acting solely as a principal is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii)&nbsp;the Agent has not assumed nor will assume an advisory or fiduciary responsibility in
favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation
to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv)&nbsp;the Agent and its respective affiliates may be engaged in a broad range of transactions that involve
interests that differ from those of the Company, and (v)&nbsp;the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting,
regulatory and tax advisors to the extent it deemed appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Research Analyst Independence</U>. The Company acknowledges that
the Agent&#146;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#146;s
research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company or the offering that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
differ from the views of their respective investment banking divisions. The Company understands that the Agent is a full service securities firm and as such from time to time, subject to
applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Notices</U>. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and
confirmed to the parties hereto as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">520 Madison Avenue
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New&nbsp;York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General
Counsel </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Paul Hastings LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">MetLife
Building </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">200 Park Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10166 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Siavosh Salimi and Will Magioncalda. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">ProKidney
Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">2000 Frontis Plaza Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 250 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Winston-Salem, NC
27103 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Tim Bertram. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Mintz, Levin, Cohn, Ferris, Glovksy and Popeo, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">One Financial Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Boston, MA
02111 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan L. Kravetz and Jason S. McCaffrey. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this
<U>Section</U><U></U><U>&nbsp;8(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the
parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in <U>Section</U><U></U><U>&nbsp;6</U>, and in each case their respective successors, and no other person will have any right or
obligation hereunder. The term &#147;successors&#148; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Partial Unenforceability</U>. The invalidity or unenforceability of any Article,
Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph or provision of this Agreement is for any reason
determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing Law Provisions</U>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of
New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&#147;<B>Related Proceedings</B>&#148;) may be
instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York
(collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a &#147;<B>Related
Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&#146;s
address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other
proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. To the
extent that the Company has or hereafter may acquire any immunity (sovereign or otherwise) from jurisdiction of any court of (i)&nbsp;Cayman Islands, (ii)&nbsp;the United States or the State of New York, (iii)&nbsp;any jurisdiction in which it owns
or leases property or assets or from any legal process (whether through service of notice, attachment prior to judgment, attachment in aid of execution, execution, <FONT STYLE="white-space:nowrap">set-off</FONT> or otherwise) with respect to
themselves or their respective property and assets or this Agreement, the Company hereby irrevocably waives such immunity in respect of its obligations under this Agreement to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>General Provisions</U>. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior
written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same
effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file. This Agreement may not be amended or modified unless in
writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings herein are for the convenience of the
parties only and shall not affect the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Immediately Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PROKIDNEY CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bruce Culleton, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Bruce Culleton, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald Lynaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Donald Lynaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ISSUANCE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: [__________] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the Open Market Sale Agreement between ProKidney Corp. (the &#147;<B>Company</B>&#148;) and Jefferies LLC (the &#147;<B>Agent</B>&#148;)
dated as of January&nbsp;19, 2024. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Delivery of Issuance Notice (determined pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>): _______________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issuance Amount (equal to the total Sales Price for such Shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of days in selling period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">______________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">______________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Last date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">______________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement Date(s) if other than standard T+2 settlement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">______________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be
withheld in the Agent&#146;s sole discretion): $ ____ per share </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Comments:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Company </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bruce Culleton, M.D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Coulston </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Agent </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Donald Lynaugh </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d664610dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g664610gsa.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19&nbsp;January 2024</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Our Ref: JA/CBY/cm/179141</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProKidney Corp.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Walkers Corporate Limited</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">190 Elgin Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">George Town</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9008</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cayman Islands</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Addressee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROKIDNEY
CORP. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been asked to provide this legal opinion to you with regards to the laws of the Cayman Islands in connection with the Registration
Statement (as defined in Schedule 1) to be filed by Prokidney Corp. (the &#147;<B>Company</B>&#148;) with the United States Securities and Exchange Commission pursuant to the United States Securities Act of 1933, as amended (the &#147;<B>Securities
Act</B>&#148;), and the Prospectus Supplement (as defined in Schedule 1) thereto relating to the offering, issue, and sale (the &#147;<B>ATM Offering</B>&#148;) by the Company of up to an aggregate offering price of US$100,000,000 of its
Class&nbsp;A ordinary shares of a par value of US$0.0001 each (the &#147;<B>Sales Agreement</B> <B>Shares</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of giving this
opinion, we have examined and relied upon the originals or copies of the documents listed in Schedule 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are Cayman Islands Attorneys at Law and
express no opinion as to any laws other than the laws of the Cayman Islands in force and as interpreted at the date of this opinion. We have not, for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other
jurisdiction. Except as explicitly stated herein, we express no opinion in relation to any representation or warranty contained in any of the documents cited in this opinion nor upon matters of fact or the commercial terms of the transactions the
subject of this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing examinations and the assumptions and qualifications set out below and having regard to legal
considerations which we consider relevant, and under the laws of the Cayman Islands, we give the following opinion in relation to the matters set out below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is an exempted company duly incorporated with limited liability, validly existing under the laws of
the Cayman Islands and in good standing with the Registrar of Companies in the Cayman Islands (the &#147;<B>Registrar</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Sales Agreement Shares have been duly authorised by all necessary corporate action of the Company. Upon the
issue of the Sales Agreement Shares (by the entry of the name of the registered owner thereof in the Register of Members of the Company confirming that such Sales Agreement Shares have been issued credited as fully paid), delivery and payment
therefore by the purchaser (for consideration not being less than </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Walkers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">190 Elgin Avenue, George Town </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Grand
Cayman <FONT STYLE="white-space:nowrap">KY1-9001,</FONT> Cayman Islands </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>T</B> +1 345 949 0100 <B>F</B> +1 345 949 7886
<U>www.walkersglobal.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Bermuda | British Virgin Islands | Cayman Islands | Dubai | Guernsey | Hong Kong | Ireland | Jersey | London |
Singapore </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
WALKERS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
their par value) in accordance with the Memorandum and Articles of Association (as defined in Schedule 1) and the Sales Agreement (as defined in Schedule 1) and in the manner contemplated by the
Prospectus Supplement, the Sales Agreement Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (meaning that no additional sums may be levied on the holder thereof in respect of the shares by the
Company). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing opinion is given based on the following assumptions. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The originals of all documents examined in connection with this opinion are authentic. The signatures, initials
and seals on the Documents (as defined in Schedule 1) are genuine and are those of a person or persons given power to execute the Documents under the Resolutions (as defined in Schedule 1). All documents purporting to be sealed have been so sealed.
All copies are complete and conform to their originals. The Documents conform in every material respect to the latest drafts of the same produced to us and, where provided in successive drafts, have been marked up to indicate all changes to such
Documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have relied upon the statements and representations of directors, officers and other representatives of the
Company as to factual matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Memorandum and Articles of Association reviewed by us will be the memorandum and articles of association of
the Company in effect upon the issuance of the Sales Agreement Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Prospectus Supplement and the documents or agreements referred to therein will be duly authorised, executed
and delivered by or on behalf of all relevant parties prior to the issue and sale of the Sales Agreement Shares and will be legal, valid, binding and enforceable against all relevant parties in accordance with their terms under all relevant laws
(other than the laws of the Cayman Islands). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will offer, issue and sell the Sales Agreement Shares in the manner contemplated by the Sales
Agreement and the Prospectus Supplement and the documents or agreements referred to therein and otherwise in compliance with all applicable United States federal and state securities laws. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company Records (as defined in Schedule 1) are complete and accurate and all matters required by law and
the Memorandum and Articles of Association to be recorded therein are completely and accurately so recorded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The accuracy and completeness of all factual representations made in the Prospectus Supplement and the
Registration Statement and all other documents reviewed by us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will receive consideration in money or money&#146;s worth for each of the Sales Agreement Shares
when issued, such price in any event not being less than the stated par or nominal value of each Sales Agreement Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Resolutions are and shall remain in full force and effect and have not been and will not be rescinded or
amended. The Resolutions have been duly executed (and where by a corporate entity such execution has been duly authorised if so required) by or on behalf of each Director and the signatures and initials thereon are those of a person or persons in
whose name the Resolutions have been expressed to be signed. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to any offer, issue or sale of the Sales Agreement Shares, the Pricing Committee of the Company, in
accordance with the authority granted to it pursuant to the Resolutions, will duly adopt by written consent resolutions setting forth, among other items, the maximum number of Sales Agreement Shares issuable in the ATM Offering and the minimum
consideration for which Sales Agreement Shares may be issued pursuant to the ATM Offering (the &#147;<B>PC Consent</B>&#148;). The ATM Offering shall be made, and Sales Agreement Shares will only be issued, in accordance with the limitations set
forth in the PC Consent. There have been no consents, resolutions or other determinations of the Pricing Committee of the Company in respect of the ATM Offering, whether in writing or otherwise, adopted on or prior to the date of this opinion.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Documents, have been, or will be, duly authorised, executed and delivered by or on behalf of all relevant
parties and are, or will be, legal, valid, binding and enforceable against all relevant parties in accordance with their terms under all relevant laws (other than the laws of the Cayman Islands). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The choice of the laws of the jurisdiction selected to govern each of the Documents has been made in good faith
and will be regarded as a valid and binding selection which will be upheld in the courts of that jurisdiction and all relevant jurisdictions (other than the Cayman Islands). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All preconditions to the issue of the Sales Agreement Shares under the terms of the Sales Agreement will be
satisfied or duly waived prior to the issue of the Sales Agreement Shares and there will be no breach of the terms of the Sales Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The issue of the Sales Agreement Shares will be of commercial benefit to the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No invitation has been made or will be made by or on behalf of the Company to the public in the Cayman Islands
to subscribe for any of the Sales Agreement Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no provisions of the laws of any jurisdiction outside the Cayman Islands which would be contravened
by the issuance and allotment of the Sales Agreement Shares and, insofar as any obligation expressed to be incurred under any of the Documents is to be performed in or is otherwise subject to the laws of any jurisdiction outside the Cayman Islands,
its performance will not be illegal by virtue of the laws of that jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is nothing under any law (other than the laws of the Cayman Islands) which would or might affect any of
the opinions set forth above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There will be nothing in the Prospectus Supplement or the PC Consent which would or might affect any of the
opinions set forth above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company was, or will be, on the date of execution of the Documents to which it is a party able to pay its
debts as they became due from its own moneys, and any disposition or settlement of property effected by any of the Documents is made in good faith and for valuable consideration and at the time of each disposition of property by the Company pursuant
to the Documents the Company will be able to pay its debts as they become due from its own moneys. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the date of issuance of any Sales Agreement Share, the Company will have sufficient authorised and unissued
share capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No amounts paid to or for the account of any party under the Documents or any property received or disposed of
by any party to the Documents in each case in connection with the performance of the Documents or the consummation of the transactions contemplated thereby, represent or will represent proceeds of criminal conduct or criminal property as defined in
the Proceeds of Crime Act (as amended) (the &#147;<B>POCA</B>&#148;) or terrorist property as defined in the POCA or the Terrorism Act (as amended) (the &#147;<B>Terrorism Act</B>&#148;), each of the Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions expressed above are subject to the following qualifications: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term &#147;<B>enforceable</B>&#148; and its cognates as used in this opinion means that the obligations
assumed by any party under the Documents are of a type which the courts of the Cayman Islands (the &#147;<B>Courts</B>&#148; and each a &#147;<B>Court</B>&#148;) enforce. This does not mean that those obligations will necessarily be enforced in all
circumstances in accordance with their terms. In particular: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enforcement of obligations and the priority of obligations may be limited by bankruptcy, insolvency,
liquidation, restructuring, reorganisation, readjustment of debts or moratorium and other laws of general application relating to or affecting the rights of creditors or by prescription or lapse of time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enforcement may be limited by general principles of equity and, in particular, the availability of certain
equitable remedies such as injunction or specific performance of an obligation may be limited where a Court considers damages to be an adequate remedy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">claims may become barred under statutes of limitation or may be or become subject to defences of <FONT
STYLE="white-space:nowrap">set-off,</FONT> counterclaim, estoppel and similar defences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where obligations are to be performed in a jurisdiction outside the Cayman Islands, they may not be enforceable
in the Cayman Islands to the extent that performance would be illegal under the laws of, or contrary to the public policy of, that jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a judgment of a Court may be required to be made in Cayman Islands dollars; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that any provision of the Documents is adjudicated to be penal in nature, it will not be
enforceable in the Courts; in particular, the enforceability of any provision of the Documents that is adjudicated to constitute a secondary obligation which imposes a detriment on the contract-breaker out of all proportion to any legitimate
interest of the innocent party in the enforcement of the primary obligation may be limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that the performance of any obligation arising under the Documents would be fraudulent or
contrary to public policy, it will not be enforceable in the Courts; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an insolvent liquidation of the Company, its liabilities are required to be translated into the
functional currency of the Company (being the currency of the primary economic environment in which it operated as at the commencement of the liquidation) at the exchange rates prevailing on the date of commencement of the voluntary liquidation or
the day on which the winding up order is made (as the case may be); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Court will not necessarily award costs in litigation in accordance with contractual provisions in this
regard; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the effectiveness of terms in the Documents excusing any party from a liability or duty otherwise owed or
indemnifying that party from the consequences of incurring such liability or breaching such duty shall be construed in accordance with, and shall be limited by, applicable law, including generally applicable rules and principles of common law and
equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our opinion as to good standing is based solely upon receipt of the Certificate of Good Standing (as defined in
Schedule 1) issued by the Registrar. The Company shall be deemed to be in good standing under section 200A of the Companies Act on the date of issue of the certificate if all fees and penalties under the Companies Act have been paid and the
Registrar has no knowledge that the Company is in default under the Companies Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters referred to
herein and shall not be construed as extending to any other matter or document not referred to herein.&nbsp;This opinion is given solely for your benefit and the benefit of your legal advisers acting in that capacity in relation to this transaction
and may not be relied upon by any other person, other than persons entitled to rely upon it pursuant to the provisions of the Securities Act, without our prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion shall be construed in accordance with the laws of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use of this opinion as an exhibit to the Registration Statement and/or Prospectus Supplement and further consent to all references to
us in the Registration Statement and/or Prospectus Supplement and any amendments thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Walkers (Cayman) LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS (CAYMAN) LLP </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF DOCUMENTS EXAMINED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Certificate of Incorporation dated 25&nbsp;February 2021, Certificate of Incorporation on Change of Name
dated 11&nbsp;July 2022, Register of Directors and Register of Officers and the Second Amended and Restated Memorandum and Articles of Association adopted on 11&nbsp;July 2022 (the &#147;<B>Memorandum and Articles of Association</B>&#148;), in each
case, of the Company, copies of which have been provided to us by its registered office in the Cayman Islands (together the &#147;<B>Company Records</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Cayman Online Registry Information System (CORIS), the Cayman Islands&#146; General Registry&#146;s online
database, searched on 18&nbsp;January 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of a Certificate of Good Standing dated 18&nbsp;January 2024 in respect of the Company issued by the
Registrar (the &#147;<B>Certificate of Good Standing</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of the executed written resolutions of the Directors of the Company dated 4&nbsp;August 2023 (the
&#147;<B>Resolutions</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Copies of the following documents (the &#147;<B>Documents</B>&#148;): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> to be filed by the Company with
the United States Securities and Exchange Commission (the &#147;<B>Registration Statement</B>&#148;) containing a base prospectus relating to the offering, issuance and sale of up to a maximum offering price of US$500,000,000 of certain securities
in the Company and a prospectus supplement relating to the issuance and sale of the Sales Agreement Shares in the ATM Offering (the &#147;<B>Prospectus Supplement</B>&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the executed Open Market Sale Agreement dated 19 January 2024 between the Company and Jefferies LLC relating to
the issuance and sale of the Sales Agreement Shares (the &#147;<B>Sales Agreement</B>&#148;). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>prok-20240119.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/20/2024 2:16:55 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:prok="http://www.prokidney.com/20240119"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.prokidney.com/20240119"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prok-20240119_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prok-20240119_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>prok-20240119_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/20/2024 2:16:55 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>prok-20240119_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/20/2024 2:16:55 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="prok-20240119.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g664610gsa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g664610gsa.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M H * /.OC/\ \B?:?]?R?^BY*];*?X_R_5')B_@7J<W\%?\ D+ZI_P!<%_\
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MC!% 'G'Q$X_9Q\+D==EG_P"BC0![/I5Q%:>&;&>>18XH[2-G=S@* @R23T%
M%?0?%^B>)K2>ZTB[:XMK=MLDQA>- 1UPS  X[XZ4 8%Y\9/ EE??99-<1V&0
MSQ1/(B_\"4$'\,].U '6V>L6&H:4NIV=U'<63(766,[@0.O\NE '-+\5_!+:
M0=4_MR,6@E,.YHI Q< $@(5W' (Y QS0!I7GCGPWI^A6NM7FJQ06%V@D@>3(
M:1>ORIC<>HXQWH S=#^*W@WQ#?)96.L(+IV*I'-&T1<YP,%@ 2>PSGGI0!V=
M 'G7QG_Y$^T_Z_D_]%R5ZV4_Q_E^J.3%_ O4YOX*_P#(7U3_ *X+_P"A5MFW
MV3/";LPOBI_R/][_ +D?_H KKRS_ '=?,RQ'\0]0U[_DD4G_ &#X_P"2UX='
M_>E_B.V?\)^AYU\(/^1V;_KU?^:U[&:_PD<F%_B,]['2OG#TB"\MH[RQGM9A
MF*:-HW'J",'^= 'BGPFU%_!VE>-]&OFW-H<KW&>F\!2"0#T'[L?]]4 5+/PN
MUU^S9?W$@S=W+/JA)&3E6_\ B%_6@!?B%XG?Q+\)/"MM9@R7FLS1QLF<Y=!A
MA_WWMH [/QCX+T.3P;HUGKNM26&D:,D8=%8".;:H&&[DX! QS\QZT <#X[^(
M'@CQ#X1O=&T30KB5XT!AN(K-8XX,$8;/51U'04 =&DCR_LNEG8L?[.*Y/H'(
M'Z"@#(^(8_XQQ\+X_NV?_HHT 9^I>*+7XH:UHG@>UU+^S]'BC4S3L#FZD5!\
MJ@]NN,]3SZ"@#J?C!<VO@WX6VGA_2@+:*[D6U"K]X1 ;G/N3@ ^NXT 8>B_$
MWX6:)H*:/!H=Y);A-LAELXF,I[EB6Y)H ;\'_$-B^I^+-!TL3C29(I+VS68?
M-&H^4J>3_>7\J *WP$\$:+KFGW^MZK9Q7S0SFWB@G0/&ORJ2Q4\$\@<],4 :
M'Q5M(_#?Q"\,ZW<:*;GPS8P"/[/!$/+C*LW&,;1]Y" < [<4 ;#ZS\,?BC]E
MTTR"TOEE62(&+R)20?N!QP<\C /TYQ0!Z[!"EO"L4>[:O3<Q8_F: //OC/\
M\B?:?]?R?^BY*];*?X_R_5')B_@7J<W\%?\ D+ZI_P!<%_\ 0JVS;[)GA-V8
M7Q4_Y'^]_P!R/_T 5UY9_NZ^9EB/XAZAKW_)(I/^P?'_ "6O#H_[TO\ $=L_
MX3]#SKX0?\CJW_7J_P#-:]C-?X2.3"_&SWL=*^</2$/2@#YD^,UK>:-\0K^*
MS&(O$-I$KCH"0Z_KF,?]]4 ?0]AHL%KX7M]$*@P16JVQ [@+M- 'S?\ #'2[
MVY^)^G>'[S#0^'Y[F8@_PL,+_P"AA30!VWQF7[+XV\*ZCK$$D_AF!P+A0NY
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MG6L-[.,2W$<*K))_O,!D]!UH GN[*UO[5[:\MXKBW<8:*5 ZL/<'@T 4M/\
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00 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140223420268000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 19, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001850270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 19,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROKIDNEY CORP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1586514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Frontis Plaza Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Winston-Salem<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">999-7029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Class&#160;A ordinary shares, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PROK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d664610d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prok-20240119.xsd" xlink:type="simple"/>
    <context id="duration_2024-01-19_to_2024-01-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-01-19_to_2024-01-19">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-01-19_to_2024-01-19"
      id="Hidden_dei_EntityCentralIndexKey">0001850270</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-01-19_to_2024-01-19">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-01-19_to_2024-01-19">2024-01-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-01-19_to_2024-01-19">PROKIDNEY CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-01-19_to_2024-01-19">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-01-19_to_2024-01-19">001-40560</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-01-19_to_2024-01-19">98-1586514</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-01-19_to_2024-01-19">2000 Frontis Plaza Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-01-19_to_2024-01-19">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-01-19_to_2024-01-19">Winston-Salem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-01-19_to_2024-01-19">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-01-19_to_2024-01-19">27103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-01-19_to_2024-01-19">336</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-01-19_to_2024-01-19">999-7029</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-01-19_to_2024-01-19">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-01-19_to_2024-01-19">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-01-19_to_2024-01-19">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-01-19_to_2024-01-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-01-19_to_2024-01-19">Class&#160;A ordinary shares, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-01-19_to_2024-01-19">PROK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-01-19_to_2024-01-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-01-19_to_2024-01-19">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-01-19_to_2024-01-19">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M756\22A.C$SSI_>5-$8F^>&645BN]@:XOI;2?)S8%P+E^YS)OU!+ P04
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MJ'7N0;#W\!J-'<V/'[?\ 5!+ P04    " !Y@C-8)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ >8(S6&60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" !Y@C-8!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( 'F",UC?,Q)![@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( 'F",UB97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ >8(S6#E%"KB*!   VQ$  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( 'F",UB?H!OP
ML0(  .(,   -              "  <T,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ >8(S6)>*NQS     $P(   L              ( !J0\  %]R96QS
M+RYR96QS4$L! A0#%     @ >8(S6!PX9>H_ 0  / (   \
M ( !DA   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( 'F",U@D'INBK0
M /@!   :              "  ?X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( 'F",UAED'F2&0$  ,\#   3              "
M >,2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "T4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d664610d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d664610d8k.htm">d664610d8k.htm</File>
    <File>prok-20240119.xsd</File>
    <File>prok-20240119_lab.xml</File>
    <File>prok-20240119_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d664610d8k.htm": {
   "nsprefix": "prok",
   "nsuri": "http://www.prokidney.com/20240119",
   "dts": {
    "inline": {
     "local": [
      "d664610d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "prok-20240119.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "prok-20240119_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prok-20240119_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-01-19_to_2024-01-19",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d664610d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-01-19_to_2024-01-19",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d664610d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.prokidney.com//20240119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-24-011267-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-011267-xbrl.zip
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M@_J(-2%JNC7K02\.PS<(2KC'HVGO;43",7'#FS8#1J&GI9IR&N=N-JHF+&\
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M!A]Z:C_4N'?@S\_LGR_+[.J*@Q G-_HASEH_E\_Q^/C3F#E#M8XVX []2NR
MFE:G3,&J37.T_9(1.%@H3_0["8DJW 9#I]YLU[5C"SR\'<&G!O<D7= R288+
M\U>SHD*W3ZXYZQF';LJD&"_GM"^!!SE:^;&R,28H(+K=EN#2I_RMFH.NNQ%'
M1UB/PN@[!OWCY[<N!!75Y^Q@=/*R$4R 88/KC1L$LV4?QSDEQD!-0$>FLVF?
M<P0_;!%6P? +RY -L.!+P1[9DR>L^?[3IT\?/_GN^7?[_FPDM3X',2U)1E'X
M45)AHM3+0 #I>X5_]1(20.DNT&KHF:-&_M@VR]3T4)_-93%<#"Q(=_A@8>A
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M"R.>/]W?Q]#<?#F[LED3L@UBILJEU'^V$'U&GH+I5\"4>J@>2?C5=&(?@[=
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M QR0E38R# AF/N;I$X1TX%%?Z7["!G!#1\I(P)]$-&7Q5^I:Z=('V>RTV3X
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M=LTI\<K69<K\,HU]9!U>Y=&C?B6])7G(0GKPP[-]KEB8,RW)#G[A)_;[NO8
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M^#=^6HI^YO!*$3!\+9779/RF!F,#9<D695HKR1@%[BW2<\,#B'\A]H0-POP
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MJ#M]7>9[9OM2'ZQ]Z5V!I-U7FUXQ0<G"PT+3HEI=\Z(VB75_W U41G":3%!
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M'/BFN!UMRXMR0]?R-L<Q':]DQJ$B]Z#FYRRUS .(0UERM]JCZT+\B#?)+0O
M;Z[>IK_5.*LS4("H-)9NKYKE0!2H[GN$W W"RDA/Q&[?6N G<>.Q&R!6\9N3
MB:^>DJ7@ZP;8!OY^YVHW,K2[$L-W5?@5F5WDU^@ 71BI71P;?XIAT%PI$J4D
ME"H0:Y=(LQLZ<C]0N2P\S88TK>#4@+@JNBVO"NJ238'-7Y,<[HT:[2S2F<)$
MB[+QKP(;].F_X&!F%9W792TF1Y8[-B[='M\CII7<TKJMX+AT+ 0\M3%M69,F
M<4"S&>34Q=#<SCIM;/CM88>(H82WJ!'T]L5EH+EH8E)[Q>]2C_<(5,PL>M,$
M\3_ P:TJSE6L1HA09&^[%Z\9DIVQU=W;FXC#!W1@E->=:9Z67 5?K2I84B*U
MJ6\+:O(,VFMR2_G*JIC6_*_;%-[(75=LFVC6ADF=C)#2OK_',;@K_)X@1U8:
MPF@AFYEH<"T25E."!O--CV5WK9"\*9GM(_[21*V*LK.QM\K;=O9WB;O:&EA;
M9+1$.@"PSBFT)6T)\((N?D<*$/@MKB6#$(OY"+L?H%/,N1J^2;%LFI 12(VQ
M+7 WFPM-6".9S^EU:29*K.:N==[B>E7AI1NSW+B$2X,'1;,YGH;6)GQX[UR7
M/?*B@@9\PH0B: 6W3K9U'G7H=4*L9Q[!55=$JJ90 2RO=YN* =,)G/=$$]NN
MLX1LB9<])ZP6\L4R>J:H<TP2QDK97/4*54#;:PKO@N<TR^X\@B^)\@1\R(1R
M<?@-=9VE@VH-P@5>P&12<BU].DL7U]A>*E]BC=D6[?72Q[#Z,]<03Y\$3ZF+
M*_C$-1YNIEO7]>)GB[GE*N$E&*\OGF"2RU5#:(VX_A7\*V8XT5\(FGZ,R0O]
M'9C<[X.MYG0",2/S^S'-B"57_ V+-"1'P B)K7KA\A94>;(?6DJ O3)X-JM&
M%[<6-_=KN7"I;1X>-RWL.,0:&WCR%QO3^_9K3.]^,3T!P @6KR%BI%9$FFPA
M]RKZ^?CL_(4!M-U-@EEIPI.8-&JM[$H>TU&Q1V=4?<IF%55E'/*YTM\YC,\/
M046MVK#N>7ZPE]ZPP-#6"6C&8IZ-2;$ZG(5\#Y_>R[YT>G9X& 3MB9#&KI&$
MU+*4[?/ O+EFO%1QRU&/AJK2N%=#Q9*6N>9X"15OT4['X@M2FS&VW'G$['@F
ML+<KQV2SXDR_HI(H4.@I0Y2$796C;!FB'-(/U'FQ1 2#5-]=4C6,!X-1&1MF
M%_$N=?$T3(8MZT2ZAB]SCW_$VTF#AJ O&>Z'A0IT@W#)#1G(,*NB$M9S_SKF
MU$DG+B)M;F3FP3$M+5B^J"EI36V(2$C])LGZ:J(/+E=:%+7#,ZWE5LJ7,F11
M:OL$.(EMP)1EJD ,ZH?D)H&FT\:")=H9Q:V1P0.?<3X'4=&1A=P= M+LM(*V
M# RK">&B?)+/]#N26+\P =*RNUEG>Y&(X:AA]) /W+!X ILD,@Q5(3D=G9FU
M7R7(0U,&8Y$^,&"SRM/.=R3T'Z*8I:X[R^%H.F>R?G>HC7,@3@%LPE3Q<-!K
M$6@56R%L@CCA"@F%T'2A$;.#U$O7OG9R\%DSMIU8BDC)W@5\Q!#J/C=! ];4
M8QL3Q])9 .:X<MT08<09SO?79"4]>9['P\&3_8/OXT9A80LVT;=L7<GFZ&=N
MLZ$;Z>38<*+[%#A>P=;OW#GY#7'JWW[S[7<_['9@:HPY'XB(>P(U3V?\<B>\
M6K[&B.'-%#J*PL8*]K&2,-LUK2E?95HZ<+=S [)N([*WAZ&P.],#]@ZT3K]X
MBI"AWM7KTW @DIJP#=.5_5 .D[ED0XT3%B"<R1##G=AJ<2W V@//_)!(K&&8
MW+I8?9&PD6SS^C"GD:"D?$\4K6;5%$+/?3[.OE4KIX@%TX8 SYCV% >_1;V
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M6.68@,H\WZ.BFJ=8K$I>\Y,#RF,=[86IIZ?[!U%:PZ7[Q]ZN@'_/N !5!B[
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M?5;7"8-4M3%[,% Q'&]!"L'F: &[@\$DCL%/&_A0.VH-ER"QAU%F&O8W:_<
MNQ=<;&-W!B1,;^:&=5/35L ,4919KOD_6D3=)VNG81D'[X2P^\K_" GR3K&+
MOQ@.M F;[FE'(*WQIT,NXQ5T.=:!+621^0:1A%1=@M*;+F<6WHGV[%7!I#AV
MPUG@9,=$,WNN1W@)TX)\U%[=:6^PDC4(*.U%IQ<7OQV^/3J)#M\>1Q>';TZB
M=Z^C=^?'IV\/S_\57?QR>'YR$:$+_@#MS*5:AWOQ^8:M'.)])ZUZM/T3NPS!
MLL=ZREQ_&'_-22V'2X?%T6A96ZV,ST," >&9=4D8]U6'W&_G78V4XQN]Z+O>
MMI8E-%*2T"I-WY-8I"![HDS 9B3LO1%-J2/'\HF$ "/\:[S<M'8QE&7_A46)
MD)D%-=A!%D>"-L4F:2#4MA&N>C4<G&D_]>5"G_EK\B&;+^?H"--E>$CLIPBV
M1&M!M%L'@\NI*LJWTOXLJ5I+(F<=KO:E(W$09@?N(_4%-^']_FO,\M,VA6?N
MM!19L+,QJ0 5,=$0#T!Q3F-J2+I41>DMXG1*4]D8#>.+@EC7Q'RNJ.D]@7".
M\;#TG)&(BM)<,Y'.Q\+Y7'^#/@?M2SP;.-!-'QWQ1]GN\>";"K1PA7#%N'70
MTP\(_*E2,LU*:O5'ABGQ!?6852.G'TR02&T)M_?#P5M)=O]T^E);EH/S7MRF
M-]@*X/2E%##O'&JB.7?-"&EL=JSR0OL"V5575/2A=NGGG5,3?*JP4^@TVOE@
M?M?0KY%3KWQY"<ND?Y7JU@78XM'.JO])1E,G_NY@4CJ-_Q&*++W),*7;4L9<
M--<PLIKI2T8>(.*3+=">NT""A*]DN )=*TQ1) =M&H-@*>&N?494-6?=-W;P
MN+W<@9N3"?,>=[ET+5? -6WOH;/4B=!J0E:FMS?EP-HSQRB#FOOE2#P.Y/*.
M11**BB0$4K,$<'R=3K#]\"&=?8H"3+AXI9R[0+*'P^#/KFC#5L%'-UAQB*^-
M0$U5V&.B^=["0(IW8X\J(X%Q[11PSFHB: T5[VD8B8S-@<1S1(A,/DZSC%N1
MD[VKKV_9/P_8E()'?8+!? 5=?*3"IA+!\-@X!X)$9B$T/2WQM[XF>1]+T8]]
M.,F4AQLUV-CH.SEF1F9J()*_PE*\<%R\"*]$&"#GREAC-&D:_37"X\+H"IFT
M$VD'T[)"_1K%?98@UUJYW T<8'@=X]J5=+"E&I;Y#!TMAFS/G,Z487M^KEJ,
M<Q<&<L&?&*F/QRGQ:@<<'5Y'] V6):"%Y_!L#PF<M8E>5Y-B.:I%F7&SR;8N
MQ0,R',@)Z;A<)!9.IT,O,7PBYF'P'))7X?OV>B81[/7;0D)_5EQ3)D?JU[2^
M1F-DBEQ3S+0Z'.!EY1$ZLGO"LB?4RWS2"KAH[ TM37;A .3@8M?<'[5-;R''
MLC),5:(H7_@+"45C5HS?!]]G^-F1?&1DJP[F/).@+PNF;26\PV&*)._"4R%*
MGLEBVB4[,*MS5/3/#M#8VGFV:W+HWMGE>C"OU_FP$9K3\]9H6;(X=W OX\LI
MP.L_3H2,?E;I!] 9)#NB&>;R)5ZV=]IV5RD&WDK'J):":\6[N.L1)0<B"0#[
MD#;[PQ+4<B)2J(CPZ;8*00H(0'7R_-$C(5(.,C)2U\4D^,YXEE#5BA,AL4BB
M9%3<I+N-MY,:U%)M8BMQ%J=7?6Z6-HHE.:7A *&V<%L_T)%3:!P9"4%]O4B_
M=%2>=L<.(H>]LG<XW4&B?-Q5/P[?$=+:@!F-]4K$W2/-FT'W2KN#IBF5PY0E
M J%NC/VS*UC+^-:A/9KHSG@"9\QK"%Q5SK]6ETYQRR@>B\JDR%D[FG<HQX2R
M2^*OK5VND1RGG/G70C;"O5TL,C/W-Z<F>C^[*+ D7+ADC_3Z02[)#I=*V10X
M.>0L7DMMY--&QU(\+^2V'8^CD&[#2 JY<#9XDO@3^;J%XZLF&LS&*$)_$B<A
MO0)A-MR1CFKLE&J&91P-DA0K!LJ"4C:SE2&C08OZBXTL_? ULG0_-)RJ>^*G
M)FV!<7J"T]@(2ZW $ZF!<31T6D4.-P.:-<?IHJB8NO&R7(+GXW([$LO%9\B'
MOOFG;W!Y")_$>I )0K=VCO]Y>+0K-7(DWB.Q[]0HH=Y14R2G%;?:$Q;/ES5W
M+1-;G3P0N<W4)O7>I7@HQCNA]_"J:+]'R9&/B7W#W87(3<$'B3!0L3M2_%-)
MO+ADU8DNSI"PN'!>-L.1P!-H73PN%#S"$UZF_K#BG+,YUQO@RSV]'O4F4JII
MKIQMZ&X,VR?8APOC[]3)*$@#)KG;2]YCWSW1ZQL7SV!#+=!,(:X#=R.(Y3=R
M>RX:3_8^_HBWCMDR^#7I/R4MA3L'/0)5MV7*TMH?LP$#";X/MI*'GE\*U1N;
MXJ:^Z?/?5>PH7 3$S)=!#UCV&,0C/VKXN9Z\G2U7 W%P7FZKZ540HQ#)SX.(
MGNWH*8?$>%I\$$W(Q8=FK%#"9S!0.<W84\<PS*Y#(K"OIGDM.69J;7  #"Y9
M&U+H<!'Y#-IW.D=V^]BG-)MS&T"#,#O +Z&"$V;58F!(DI6!9:^*T!81=[6,
M%L$56P[=$Q1?;\S1T7*&55,AN2HF=>2R,.$OJUL)726O1=6QV,+@[$5!]K 2
M^%_2JK@(Q8A7A5H<D./*L];&,ZZD<H.U\W1GM OV&H7.N6JWV<>01ROAU*/N
M28,WF1"I/A+3U78+3,A5YXT[O-Z8(NVCK8=%%2/Q7A #*N<4C%&R,_P>MO^-
M%4,W2>;2TE9:O)G 9&?5!36*8+2UU*IS&F!BPUVS] KK'%():&GWN%U*96J;
MZKB;=JP)W.#R2%ZZAGYG%=Z\)3V0P2>2)3**T0EFCR+WN Z/01>+F;GLD&D*
M@SIE6=PV?6YI\%!CJ )I9A'_(?XP9RM::66N):S-I>9O'M:.ZO:%\#W"K_'R
M>&H,])19+>$0E0VW]4 $S,R(<I;RY["N/!OD(&W '(ULY86X$7DC$L^)""H9
M-%QZ+'D2!.3X.\4T&A%MPY!A5';@QF\/(J'SF>T^5"[QQO=+_GF9((J!6E5&
M9QJLB*.3>NQ[R71B;IRL5@W%3QXJ1D1QS;%]4*6%&@V8SBWU<1D1=S&R+V!7
M,RD@)W]95)33R0TSCIO#8V# DGR$2JIQ0_L0%9=H8SL9V'+7\]E85 W5V!&L
MX>,'[P]?"5(PAL.2!HK1FV,$*@&EM"87EG:T$9<0U-B:WH'P-1@2'L3FTO"L
M@EVW8.-^6^2/N?Y/,UBF]$+:,10U*E:7-#*<+6&+P+8>O!-PQALD/C7;RB0V
MX2_!@_T31N#T!W<WIT.\H>)P*,*:C(G)+#=)D9 Q&!PZN(]TJO-P@3?4#"R"
MY379D8=0/6.2D->I&MZ'E(/"ZY8/$/53TM8U)=U,S20_K_(B:4*1-D:8I'0+
MSCB50AMB-*4X-]]M),IM_K/+_ R P";M0P;?'2\&<%[8= L..#Q;"NG-+"R[
MF^OFW#^+A]CQ">WXB9A4'374<H<4M*44""@J O WS3%GB?619#;HD!OV$B,V
M?6^^GH<$F1_$\"% /&'Z,D19;B"LV;'U2W;DW(I#1-9%. ,BYC#S:#/N3-.3
MU]HC,<VORN2&>Y[!8NTV"YMU[;[<T..3_:^AQ_N%'IWP.1 0=Y(J-6EO0]B!
MZ 6EDG2EI6B?H?M N)_8?#OW_0.1F9V)TWN.5B#U[5Q[P#"(IF%; X2)5XT-
M",P:3^8D)35,UCBQ"A2>SF6BOY- 7**LS%))Q8T9JA?&45%M=$<]1-12KK:"
MSVTLW>%BN,"RA>MV.L$]D>[FMCM65],OHQ%\ U5?EX^6XW4VRO!?E6!]?+V.
M\+)Y #^M)LZIK"NI4[8DZ:B;7Z.A]$_Q=0PU]8ZEATQGQ>VNTFE-I"5HV!U^
MR=4^,5=6^!YGH7L<<^DF$3.8<K!&,5;-?K/:7M;H>]$H'^4%)V4('X>#5.;I
M2KFFUUPOW<3YO:4:PG@I(3P-3../.^20( H<?TH_P%7"]XK>U<,!?]G1/I;N
MF(I [-)Z*% M*1M'E4R71HK;Y_JYN+3R&7\,,<Z6\*OW*U>)ZU)IN:72E>IT
M$I*C)$\F2<P!?7"9/)S06BBQR(!*MK^P?(3X%;[\XOT*?()E>8,=,APY"1+M
MI?,"%,MD.6?O4KY'K\?$!=JT(*ZQ,FZM>@0##W(CNR)QOF"UJSA8;**X-A%*
ME0[=M!?-&F 30'+"!,=Y!-9>V+,XS.<;;26G>?TCK?(S]4-K93*.7I^^/3\4
MLDK:-"F0F[@VE%VC:U>M4=A:@"9]"LOK[YLL6"%S )$LV=M 7:-#]6\1K1V*
MMU&&9<NZ73>=L#I&P,TL2&618+:HN+6TLTP8V*/).?QO8 9N*8*9=U&_# >6
M^\5-(:F(LKH6UM+F?<&E%N#LF4P%S<#GER,WC8V/I7)G>8C[5E3-8!]X98E%
M.QMW6MN.'#3'FCZZ+$T_H*[5PE<@9K:X;>R"&1(FN)H2Z"/A8-2FS+HS*R97
MK#2;5HPMS,,[3^LW^2J7$LXN6GPK[T:#8%F;GZ/WZ9E#5OC;LG)<)M,Z&L-^
M<]:QO0:,6''K+!$D*]+M16[NVTR14]<V@%1W0+#8B^I7/,&Q5KT1\A%H9+:R
M]Z9R'3">R<0T!)R]<[@;_>6[Y_'^_CZL 54OM03!M:OIZ$JC<*F_'.@S6K)$
MB<G+,KNZXK-V<N- (AV61]$3-G%1:"+[9*Q1$E1_WJGJ#W_>?8!"NF=[T>'Q
M\>GEZ;NWAV^BHW?_.'E[^/;R@0KGK...]:*YLZ'%C7<BX#+1KA(,<XT391NT
M<,&.![$44QP^G57I+864!1YH2.Q^_/Q1SD3"&5@;=,6D+)XWCJ,;QSW5,UUA
M+!<N0+H KL4A:"[F>3%2[*'S0< JF3E2!C[]RGL02/U(60C8(FP0[L31P3.\
M;@Z>JV8,9B5WO[3,H[KB#&&:'"0A]##-*DSW-!\C2M!9!9+:127"5V:JV44P
MS5"S$@Z=)P;S?(V-4[8((Q_L/_X_ECDHHW7)EYZ[HO&T]<_ZNZ<APF*;.7J^
M8!LFXL"I]>4:OO([" ,O.[US8-2^APU>&-A@J_RR!;8PDL[+^,0^-*U]_TA;
M,6*%S/1Q3X07U13/, $R9B><9^<-:JU?55( LUT&*R067@!@YOBD11GC]P/A
M(NR(!S9C=QT,G&1SK#9R@[EP@S%HDECF(]O2Z+:"?EXT2[%%8D&1!I6K=I5%
M5H4GXAEYZ*EPB/-PHL[1!!O%0.LGS[!JL ]E#==6__EQB&9://LX_!+__'3_
M5>_#=W>_W-+5)P=?HWQ_0NEJ0_J:%]2APZ@HN<.ZY!E=5,2C!HXP9A_1O4Y#
M]U/SX>XZ<]:Z*4M:<;D1VZ>Q<C2GZ.51)9[C=PF9<(BWQ!]R5&EN@'(?VO"W
MO)E.&%V-,D52AZRMY*<%&/B/#2A 8TX2I.\+PW%HC,_EMT]PQ7O"=1*T\<\-
MIJ6I@"UC;D%,MG..GN9J_;PV#!<G-ARLG]DHQ=Z9E4=4Z#5_$P[0!7S]M:06
MC.P!N.P+9@W2%)J:3N[9E@9C_=#[)^YCAOT[QVRL'[=U%/+D&?%DL*0TS176
MUYC:LG(2V1=A%0O#"H=_A:?KJ;BV>4YX&H4 V@PD6P#J5<)?_E@6M7:@@7WN
MQ 71QG@5DNK-38A&YVMQTP-\=#IADTCJ'[RQ(+1(#NXZM0/0&9$D"WV9^WI6
M9T'XPT[944UKU:>PO% 52D/,V,HF?>W=?12ZX8 WRI3#M;'_KDYRA* Q+8JL
M"PGJTN=GV50#1&P7Z6-)B)-REN%W,8&?85AO7G!]7\AF%80J0IP<S\!B_US
MUM4^]!@-3QM<SS';$!RG:-P1;*"8*7=4@Q(&D>",7MFP2A5?K6%]2AD-KHH=
M(6R?#I IT)SUFAGW1QR/EN9X.-3"89B4N+"QYY9"P$\P 7MCH7]ENB5?-N4(
M^7FG"Z0"$IIT\9:IGHZVDH"<""S$QJU:PX2\[2Y!AY[U7+2 U5CAZ*K"XU_,
MKQT02HU]L-"QH_;2T#_3B?00E&G"YGT!]C]%E;@?3.,#)H&8RPFAWHKO4Y^G
M,%'\C%G2^7@A@P/"M2DFEY7@Z"(4"/$AM]=IJVMJUL3=.T!6262 V.$'_ /'
M=88(,"TH(W*H,$P8<G99HX?6W0.T[KH##3QO2'5KXLE=A[537^P8YR;T:Q""
M@>+X;&>ZNRO1,#;EQ 44Q\<I%QMH0"[599EGU75$^@CF?)L[\&T##>4/2##W
MKO-A)=!L?R;WDCU)]&%ENVV2))+.^L\4V>CN$DL ]4!DL>3&22SCVKN.;L (
MW%@C81SK%S>#:&D+6\@TV8@J<SFT="LQ.);87[9]-I3>:SF8)DB)BRTY;A/"
MW:DEU9GL;R.@';]X(.D/@("<>,('C1[3H.6'"LQ-[ATWQ9TC#LSAH/]6H2OB
MIU-T74^QBQ.7!M%Z.KM2/ZQ[MQDYP(DS\RE_3&RP$&]HT1]L*O>&']JV*M5.
MF]=9$4!LMM&)4K66*Q>I,?DXJ!8,JAE=W.T*J:JZ"DJBIN1M<KHQ"3J",;P/
M98T9$4P%UD(VB?\$'U'_L53,.C, )B#&"Y)7"FNQ4:K?=9-'B]/L&*J+JI@B
M'*?J^TKCR'#EF=.FFY%J#5"P2>:0PI=YN*.Z<0"*=VNGC6G91!_(>PM_J[A:
M;KU63"C,J"(EZ+'E]EN%U\1#4/'KC(&WJ+CQR5]PY.S)U\C9)U7>*2GOW]@U
M[W'+V6CO8U[VVH98!000%0\'"'^* ^ 39_D91X%_TQ)S9Y!1MSGZ1NOC<7 ,
M34EA>!@-K8(>2L5!^#_-Y\M<T#""B1":7[V5*X?"H5[Q&N?SA\V3C]"A$D8C
MY.END9'L/^\_P4U,=8"U"'0;.81A(:I38#UCE/)KNP'"Y9-4%IW4N^N-4M;/
MZWQ.&3+?/39%5/\3#4NPOZXRZ>E$BKUO03[NVD3G\\^\-]W7^K9Q4U1.*NI8
MZW\"0*+>T&":-J_H=4/\-+?WALL[YBABZ95$^QK?L(YKS7-9S.&@]\X7Q1*B
M^?MER:LMQ-!@BP0B%:"LP"+S>*.^0:_=3Y:L5OJSU\+J>XG?(S99MC"Q*G-<
ML)K1D*-+>H/#/(9VB[S (.V:M;/HS0SBAN9BS92D]IQY"E[);HOONJMNE1/$
M$FC1&@1D+A;N>@Y29>%4U(+G@@KK17:GEG99L#C*)72*]&_T?EQC2ACI33HK
M%G/!D"11,^SUT9+2?_)#PB$,=()=*GT9F)Y2?]?)-1>V/UV?K+#A<7[TQT4O
M@M%];#B#Y_UQ\0Q,<S J@B/>26T:5DA0O1ET:^LTGUKLB)NMO=AA"NDLDU1'
MX=J".E0?;U<C:N*GBJ#4]2_X_RGX%&R6U$AOW"W1;TC.(A0P&RD@%IM#%9LL
MMC_5KZ=<]AT-E [_N$,>>J7H8Z_RN[ZH[[(FF":[ ?A6O@Z6N;FK\)O7Z6SR
M &&S*S9P76Z>=W:#P=LV.FABU&2<2M4YI1NT-=;>)$%XW^Z+^@D^?- ;&&]#
M@)[B5;LF1O$Q]Y49:J-XWF<>>'8X>\>/;2!%.H?:%3\^P Y?"XF@VGD]-R,>
MDZ:SO0FK$AD8W7 P0^"7&"9"?/2?:&-%WL3JSOT67MNY':<GB*V\PU80*^3A
MP!0'\ =V-P F"(.>!.9_;>NJ[+L*;2\>J+/&M[L],3EK:"/YZG;.G'%0;MW)
M^H)K5Y]^C<W=KW;54: U4:0F+;$^)APSG;':=W^@1/$?M_#8V@3B+USQ&ZDB
M2S??HV.&@]ZKH"C-L%T]'C$?M&KO4"O\#K^L)IFT!C7>%]<+!;&7]02;D:&;
MV,0"UE/DXRN@RBZ^;"HZ9R>1 X*,45/W$2.CSO?K].R:NH9V*^\WP>_A/AG[
MFRCU[FV!LRNUQ@3G;3<0*L*_$':&@@*T9#VYX2[X DFDPT-1*)BEN84+$;H1
MP8([]/&6: 66+S(DNC-Q6+J[<F4()J''ERU9MLBMK%>"G:-9WR;,J7UPFB^F
MEGC(]#1ML>'XKA\-V\D!Y5"4A7#*4RGNZ$FOY,&NS8AE>1FGZ!'A<@H1M_B*
M1<[TBT02B,=PE[&1+6ZU,17AK5G^_O#!W8X(K5 +M.M\[I!R4"Y^P\3LT;V[
MNJQBL'*Y-K/B!IDV?70WH&03JO)3S9MW7: /)BQ0V4<6#H]:"N)48P<*F7X1
MM7S=6/P*V-/>8^6!0F$^TG$+!=>&YW=&M6&#CG)>NHS%1O#$U7,@9*?/;6&O
MLG</'JZSD5:&M\#J;4=O7' #7S-#?^J[T5JP\%*E;TOT[;W%[-.^?-Z7[G?5
M[=MNLE2D[^Z$3=7VKIA]?<D].!]PJNS%7W7PQDI@O0T1I6VF9U'9BT)MX!0O
M56FM+85OE+ZC%.KI**)9P33O3JQUK?M+P_O\]5$:' [=(S(,M(5W  UA.R?T
M\B/CY"L(CB]W6![JM"J,4A3=)B1Q56E4FU8J,+"DV)#OSZ+64F986EDR";KJ
MQ_C%1&/GJXN2#U*2U#.3<$%(2?6K:%E*0Z8JO]E$'D%2K+-$1AC94%LYO]LX
M!<[ B\6\\\!N6;)@M>0%%K&-PH!P[C9VVYDJ%K?MFKG@."0#T"@?"*#U!DS?
MYG2(&TM0FEEW:<\M -ZWGD9; H.;T=V?/<+R.Y>E)B5"Z"M3RN!HUCI,DP[
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M!;<L5EIZ G6+L^=/DZ' R73X@\PU=D#5W;65_969W:4_ROWA]YP(/ PZ8IU
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M#B\L<,HX+T7)4E:4>IR6N-,N@"4OAUT+F"/)"4-!)+@JB/!J8F:LTN'@!?<
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M195)D&'A-M#-#0D3$>[@80=VG7 C%:7<?6A1(J24Q)7X9Y7CA\00&$:BOI*
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MHN*2<F<TAY^X>!DU6Q3;@+H-7*P)1,,;OEQ1F,N5@;8Z++%U18*):!L8CH+
M+H4TO11- @N,,8<2Y0<V;'&,C)E5I4ZQG$XXWGX)%YE:FE!&V/JN9=/X/@8N
M*+4DM!(OI0OP(%B#'%T7[.\ XX?S.ZE9)6<0'_.7Z9#3OC )7BC$B]B:NV0*
MR9N,U[2//FH\U?UU:N^AU-Y$E;V*JMA+AA3*9];6K"0L)Z!_@B93ZUDCD6>)
MZ207YFB^P/K'$4I'H?D#:*!Q<H,][EC8'JP(8\<N8GQ7_5+TYB*)7( \)T9
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MW+2@55#"0R'@WGNR2,:O_PI1UOLLL_9/W9279#%8; /Y.Y^Y"<PJK5%N0:4
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M^UKA#-U1[#MS9["!JY<*K"*/(!  @DDF8)7?N93=LHF0Z(]I',4/9=8;6@8
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M/>_;&!72W-A("G% 9&CX^B4CYUJER*RS@4V<DA6IZ.< V A645GD6<^O58H
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M@;YA37K=CL84>.[%VH)U\ $^4CTB6)TK;<IJCLK?TI_7U'AK:ES1U "#U('
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M?CSY G]DY4;PF<0DD 06@4R(@-]6-(Y&_I%_/#P:^GV_G"9(H/4@"A(R@N'
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MTJJZA$ARU;1?-R1/%PIS]3>YB(.9+9*/DCI"TMPZ-QQT0=(@A(3D-V70TLY
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M9,!$NXV+\HXKM:5_NU"^BV:_8T?M^1]02P,$%     @ >8(S6+(/N!7<!
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MS*/+ZR/FQ3R(BR5_ U!+ 0(4 Q0    ( 'F",UCG7I=IP1(  *=R   .
M          "  0    !D-C8T-C$P9#AK+FAT;5!+ 0(4 Q0    ( 'F",UC>
MN$I:?YT  $;W @ 0              "  >T2  !D-C8T-C$P9&5X,3$N:'1M
M4$L! A0#%     @ >8(S6/$D8M-J&@  **<  !               ( !FK
M &0V-C0V,3!D97@U,2YH=&U02P$"% ,4    " !Y@C-8'3AM<S\#  !/"P
M$0              @ $RRP  <')O:RTR,#(T,#$Q.2YX<V102P$"% ,4
M" !Y@C-8L9=<7JH&  "D20  %0              @ &@S@  <')O:RTR,#(T
M,#$Q.5]L86(N>&UL4$L! A0#%     @ >8(S6+(/N!7<!    2X  !4
M         ( !?=4  '!R;VLM,C R-# Q,3E?<')E+GAM;%!+!08     !@ &
+ 'T!  ",V@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
